Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Wednesday Julyv io

Poster Exhibitions

WePeB5949 Evaluation of HIV counseling and testing during
antenatal care in Brazil
V G Veloso M Vasconcelos, L A Matzenbacher,
A L R Vasconcelos, A Grangeiro, M C Portela,
A N D The Pacata Study Group (Brazil)
WePeB595o Resistance testing in antiretroviral naive H IV
positive pregnant women
S Juethner, C Williamson, M Ristig, P Tebas,
JA Aberf (United States)
WePeB5951 Lactic acidosis in newborns exposed to HIV and
antiretrovirals
A Noguera B Perez-Duenas, L M Tello, R Artuch,
M Garcia-Fructuoso, M C Munoz, C Fortuny
(Spain)
WePeB5952 HIV transmission through breastfeeding: is there
a critical "cut off" of plasma viral load?
N Z Nyazema', E Gomol, P Ndlovu', H Friis2,
E Opperman Staff' ('Zimbabwe; 2Denmark)
WePeB5953 Impact of Highly Active Anti-Retroviral Treatment
(HAART) during pregnancy and breastfeeding on
Mother-to-Child HIV Transmission (MTCT) and
mother's health in developing countries
/ de Vincenzi P Gaillard, T Farley (Switzerland)
WePeB5954 Reaching out and scaling up of PMTCT
programme in the city of Mumbai, India
A Dr.Goqate, P Dr.Gurnani (India)
WePeB5955 Antiretroviral therapy in pregnancy: exposure
patterns over time and the prevalence of birth
defects
PM Garcia D Covington, D H Watts,
K Beckerman, H E Fox, A Parker, A White
(United States)
WePeB5956 Pluridisciplinary care in a mother to child
transmission prevention program in Le Dantec
Hospital
A Diou, M L Cisse, C Cisse, Y Wane, L Diaw,
NM Sall, S Mboup, I Ndoye (Senegal)
WePeB5957 Effects of substance abuse on vertical
transmission
P E Vink, J Farley, P Nair, S Hines, R Flinko
(United States)
WePeB5958 The care of infants included in the Senegalese
program of prevention of mother to child
transmission of HIV
H Sy, A M Diack, N R Diagne, A Diouf, L Diaw,
N C Toure, / Ndir, A Gaye, N Mbaye, M Goumbala,
M Gueye, S Ka, Y Dieme, P Dionne, N M Sall,
S Mboup, I Ndoye (Senegal)
WePeB5959 Use of zidovudine postpartum to the newborn
and HIV vertical transmission
A G P Dos Santos M VArnoni, EN Berezin,
F] Almeida, MA P Safadi (Brazil)
WePeB596o Prevention of vertical HIV transmission in the
Bahamas, 1995-1999
M P Gomez', S E Read2, P McNeil', M jervis',
R M Bain', C Major2 ('Bahamas; 2Canada)
WePeB5961 Experience on antiretroviral therapy during
pregnancy: results from a large multicenter study
/ Solfs, ] T Ramos, C Fortuny, I Almeda, I Bates,
] Beceiro, I M Bertrdn, ] Casabona, P Del Barrio,
P Ferrando, C Garaulet, L Garcfa, M T Garcfa
Fructuoso, A / Gdnzalez Espinola, M D Gurbindo,
I M Herndndez Garcfa, E Iglesias, IS ]imdnez,
M / de Ios, D Ldpez Gay, P Miralles, MA Muhtoz,
M C Mufioz, E Mufhoz Gdlligo, A Mur, M L Navarro,
S Ofate, I M Pehfa, F Pulido, F Regidor, MA Roa,
C Rodrigo, B Rubio, R Rubio, ] Ruiz Contreras,

S Salas, N A Salcedo, E Sdnchez, M JSantos,
P Segovia (Spain)

WePeB5962 Comparison of virologic response in a cohort of
women and men treated with Nelfinavir
containing HAART regimens
P Keiser, N N Nassar, G Koen, S Moreno
(United States)
WePeB5963 Medically eligible women not reporting use of
HAART
M H Cohen, ]A Cook, D Grey, S JGange, M Young,
L Hannau, P Tien, A Levine (United States)
WePeB5964 Gender bias in clinical trials of AIDS drugs
MA Pardo, M T Ruiz, A Gimeno, L Navarro,
A Garcfa, M V Tarazona, MT Aznar (Spain)
WePeB5965 Gender but not ethnicity predicts CD4 cell
increase in response to sustained virologic
suppression (SVS) from highly active
antiretroviral therapy (HAART)
T P Giordano, F Visnegarwala, JA Wright,
A Adu-Oppong, EA Graviss (United States)
WePeB5966 Differential penetration of protease inhibitors [PI]
and non-nucleoside reverse transcriptase
inhibitors [NNRTI] into the female genital tract
[GT]
SS Min, A H Corbett, N Rezk, S A Fiscus,
M S Cohen, A D M Kashuba (United States)
WePeB5967 Gender comparisons in long term responses
among patients receiving nelfinavir and dual
nucleoside reverse transcriptase inhibitors as
first ever highly active antiretroviral therapy
FJ Palella, Gathe, A Brutus, M Sension, B Allen,
P Morrow (United States)
WePeB5968 Use of HAART in women: similar response but
greater toxicity
M L Nguyen, G S Nagy, I Hernandez, J Holtzberg,
C Del Rio, ] Lennox (United States)
WePeB5969 HAART and evolution of abnormal cervical
cytology in women with H IV
D Money, C Hankins A Rachlis, F Coutlee,
W Wobeser, K Pourreaux, J 0 Shu (Venezuela)
WePeB597o A comparison of the pharmacokinetics of
nelfinavir in African-American women versus men
with HIV infection
R Sharma B Bellantone, D Singh (United States)
WePeB5971 Dyslipidaemia in HIV-infected women before and
after starting highly active antiretroviral therapy
(HAART)
M Pynka (Poland)
WePeB5972 Safety and efficacy of Lopinavir/Ritonavir in
women in a phase Ill study of Antiretroviral-Naive
subjects
P Cernohous, B Bernstein, J Mosley, M King,
E Bauer, E Sun (United States)
WePeB5973 A prospective study of HIV related hospitalization
rates during the HAART era in an urban and HIVreferral hospital in Miami: gender and
ethnic/racial differences
H Archer, M I Miguez-Burbano, A Rodriguez
X Burbano, A Pilarte, N Rodriguez, G Shor-Posner
(United States)
WePeB5974 Effectiveness and durability of non-PI vs. P
containing combination therapy in anti-retroviral
(ARV) naive urban indigent population
F VisnearawalaI A Wright, T Giordano,
A Anooka, M Q Hasan, EA Graviss (United States)
WePeB5975 Physicians and nonphysician clinicians: is there a
difference in virologic response to antiretroviral
therapy (ARV)?
D L johnson, S asuja, MA Leal (United States)

Wednesday

XIV International AIDS Conference BARCELONA - JULY 7-12

163